Implementation of Best Practices in Pancreatic Cancer Care in the Netherlands
JAMA Surgery · 01.04.2024 · 159 (4) · 429
DOI: 10.1001/jamasurg.2023.7872 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift JAMA Surgery, erschienen am 01.04.2024. Verfasst von Tara M Mackay und 40 weiteren Autor:innen. Beteiligte Einrichtung: Amsterdam UMC, location University of Amsterdam, Department of Surgery, Amsterdam, the Netherlands. Hauptthemen laut MEDLINE: Gemcitabine, Pancreatic Neoplasms. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Importance Implementation of new cancer treatment strategies as recommended by evidence-based guidelines is often slow and suboptimal.
Objective
To improve the implementation of guideline-based best practices in the Netherlands in pancreatic cancer care and assess the impact on survival. Design, setting, and participants This multicenter, stepped-wedge cluster randomized trial compared enhanced implementation of best practices with usual care in consecutive patients with all stages of pancreatic cancer. It took place from May 22, 2018 through July 9, 2020. Data were analyzed from April 1, 2022, through February 1, 2023. It included all patients in the Netherlands with pathologically or clinically diagnosed pancreatic ductal adenocarcinoma. This study reports 1-year follow-up (or shorter in case of deceased patients).
Intervention
The 5 best practices included optimal use of perioperative chemotherapy, palliative chemotherapy, pancreatic enzyme replacement therapy (PERT), referral to a dietician, and use of metal stents in patients with biliary obstruction. A 6-week implementation period was completed, in a randomized order, in all 17 Dutch networks for pancreatic cancer care. Main Outcomes and Measures The primary outcome was 1-year survival. Secondary outcomes included adherence to best practices and quality of life (European Organisation for Research and Treatment of Cancer [EORTC] global health score).
Results
Overall, 5887 patients with pancreatic cancer (median age, 72.0 [IQR, 64.0-79.0] years; 50% female) were enrolled, 2641 before and 2939 after implementation of best practices (307 during wash-in period). One-year survival was 24% vs 23% (hazard ratio, 0.98, 95% CI, 0.88-1.08). There was no difference in the use of neoadjuvant chemotherapy (11% vs 11%), adjuvant chemotherapy (48% vs 51%), and referral to a dietician (59% vs 63%), while the use of palliative chemotherapy (24% vs 30%; odds ratio [OR], 1.38; 95% CI, 1.10-1.74), PERT (34% vs 45%; OR, 1.64; 95% CI, 1.28-2.11), and metal biliary stents increased (74% vs 83%; OR, 1.78; 95% CI, 1.13-2.80). The EORTC global health score did not improve (area under the curve, 43.9 vs 42.8; median difference, −1.09, 95% CI, −3.05 to 0.94). Conclusions and Relevance In this randomized clinical trial, implementation of 5 best practices in pancreatic cancer care did not improve 1-year survival and quality of life. The finding that most patients received no tumor-directed treatment paired with the poor survival highlights the need for more personalized treatment options. Trial Registration ClinicalTrials.gov Identifier: NCT03513705
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Amsterdam UMC, location University of Amsterdam, Department of Surgery, Amsterdam, the Netherlands.
- Cancer Center Amsterdam, the Netherlands.
- Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, the Netherlands.
- Department of Gastroenterology, Regional Academic Cancer Center Utrecht, University Medical Center Utrecht & St. Antonius Hospital Nieuwegein, the Netherlands.
- Department of Surgery, Leiden University Medical Center, Leiden, the Netherlands.
- Department of Medical Oncology, Regional Academic Cancer Center Utrecht, University Medical Center Utrecht & St. Antonius Hospital Nieuwegein, the Netherlands.
Zitieren
APA
Mackay, T. M., Latenstein, A. E. J., Augustinus, S., van der Geest, L. G., Bogte, A., Bonsing, B. A., Cirkel, G. A., Hol, L., Busch, O. R., den Dulk, M., van Driel, L. M. J. W., Festen, S., de Groot, D. A., de Groot, J. B., Groot Koerkamp, B., Haj Mohammad, N., Haver, J. T., van der Harst, E., de Hingh, I. H., …, & Dutch Pancreatic Cancer Group (2024). Implementation of Best Practices in Pancreatic Cancer Care in the Netherlands. JAMA Surgery, 159(4), 429. https://doi.org/10.1001/jamasurg.2023.7872
Vancouver
Mackay TM, Latenstein AEJ, Augustinus S, van der Geest LG, Bogte A, Bonsing BA, et al. Implementation of Best Practices in Pancreatic Cancer Care in the Netherlands. JAMA Surgery. 2024;159(4):429. doi:10.1001/jamasurg.2023.7872
BibTeX
@article{Mackay2024,
author = {Mackay, Tara M and Latenstein, Anouk E J and Augustinus, Simone and van der Geest, Lydia G and Bogte, Auke and Bonsing, Bert A and Cirkel, Geert A and Hol, Lieke and Busch, Olivier R and den Dulk, Marcel and van Driel, Lydi M J W and Festen, Sebastiaan and de Groot, Derk-Jan A and de Groot, Jan-Willem B and Groot Koerkamp, Bas and Haj Mohammad, Nadia and Haver, Joyce T and van der Harst, Erwin and de Hingh, Ignace H and Homs, Marjolein Y V and Los, Maartje and Luelmo, Saskia A C and de Meijer, Vincent E and Mekenkamp, Leonie and Molenaar, I Quintus and Patijn, Gijs A and Quispel, Rutger and Römkens, Tessa E H and van Santvoort, Hjalmar C and Stommel, Martijn W J and Venneman, Niels G and Verdonk, Robert C and van Vilsteren, Frederike G I and de Vos-Geelen, Judith and van Werkhoven, C Henri and van Hooft, Jeanin E and van Eijck, Casper H J and Wilmink, Johanna W and van Laarhoven, Hanneke W M and Besselink, Marc G and Dutch Pancreatic Cancer Group, Dutch Pancreatic Cancer Group},
title = {Implementation of Best Practices in Pancreatic Cancer Care in the Netherlands},
journal = {JAMA Surgery},
year = {2024},
volume = {159},
number = {4},
pages = {429},
doi = {10.1001/jamasurg.2023.7872}
}
EUVIMED